The AIM technology has been designed to orchestrate specific immune system responses in a highly controllable and reproducible way independent of the healthiness or abundance of the patient’s natural antigen presenting cell (APC) population. Natural APCs are major players in the body’s immune system as they direct the immune system cells in attacks on specifically targeted antigens and cells. However, under certain disease conditions, natural APCs can be damaged, absent or inactive.
Central to the AIM technology is the artificial Antigen Presenting Cell (aAPC) which in its basic form has four components: the bead that serves as a synthetic cellular core; recombinant HLA-Ig dimer molecules that “present” a specific antigen to T cells; the antigen to stimulate a specific T cell response; and a co-stimulatory molecule that facilitates activation of T cells.
The AIM technology holds great potential for use in immuno-therapy because aAPCs can be readily engineered in such a way that a highly specific immune attack can be directed toward any foreign substance or cell type in a patient’s body.
BIO 2013 International Convention
NexImmune executives attend the BIO 2013 International Convention on April 22 - 25, 2013 for business development meetings.
University Research & Entrepreneurship Symposium
NexImmune executives present an overview of the company at the symposium in Cambridge, MA on April 3, 2013.
JP Morgan Conference
NexImmune executives attend the conference on January 7-9, 2013.